NFKB1 and melanoma: Thus, targeting IκBζ might constitute an attractive approach for sensitizing melanoma patients to immunotherapy, especially as IκBζ deletion would affect multiple oncogenic pathways, including NF-κB, STAT3, EZH2, and HDAC3.